Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/2/2019
Start Date:August 1, 2018
End Date:February 22, 2020
Contact:ADC Therapeutics
Email:clinical.trials@adctherapeutics.com
Phone:954-903-7994

Use our guide to learn which trials are right for you!

A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of
Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large
B-Cell Lymphoma.

This is a Phase 2, multi-center, open-label, single-arm study of the efficacy and safety of
loncastuximab tesirine used as monotherapy in patients with relapsed or refractory DLBCL. The
study will enroll approximately 140 patients

Loncastuximab Tesirine is an antibody drug conjugate (ADC) composed of a humanized antibody
directed against human cluster of differentiation 19 (CD19), stochastically conjugated via a
valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin.
Loncastuximab tesirine has been designed to target and kill CD19-expressing malignant
B-cells.

A 2-stage design will be used in this clinical study, with an interim analysis for futility
on the first 52 patients. If ≥10 patients respond (CR+PR), the study will proceed to complete
full enrollment. Enrollment will continue during the interim analysis; however, further
enrollment will be halted if futility is confirmed.

For each patient, the study will include a Screening Period (of up to 28 days), a Treatment
Period (cycles of 3 weeks), and a Follow-up Period (approximately every 12 week visits for up
to 3 years after treatment discontinuation).

Patients may continue treatment until disease progression, unacceptable toxicity, or other
discontinuation criteria, whichever occurs first.

Inclusion Criteria:

- Male or female patient aged 18 years or older.

- Pathologic diagnosis of DLBCL, as defined by the 2016 WHO classification, to include:
DLBCL not otherwise specified; primary mediastinal large B-cell lymphoma; and
high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements

- Relapsed or refractory disease following two or more multi-agent systemic treatment
regimens

- Patients who have received previous CD19-directed therapy must have a biopsy that
shows CD19 protein expression after completion of the CD19-directed therapy.

- Measurable disease as defined by the 2014 Lugano Classification

- Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block or minimum
10 freshly cut unstained slides if block is not available

- ECOG performance status 0-2

- Adequate organ function

- Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test within 7 days prior
to start of study drug (C1D1) for women of childbearing potential

- Women of childbearing potential must agree to use a highly effective method of
contraception from the time of giving informed consent until at least 16 weeks after
the last dose of loncastuximab tesirine. Men with female partners who are of
childbearing potential must agree that they will use a highly effective method of
contraception from the time of giving informed consent until at least 16 weeks after
the patient receives his last dose of loncastuximab tesirine.

Exclusion Criteria:

- Previous treatment with loncastuximab tesirine

- Known history of hypersensitivity to or positive serum human ADA to a CD19 antibody

- Pathologic diagnosis of Burkitt lymphoma

- Active second primary malignancy other than non-melanoma skin cancers, non-metastatic
prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the
breast, or other malignancy that the Sponsor's medical monitor and Investigator agree
and document should not be exclusionary

- Autologous stem cell transplant (ASCT) within 30 days prior to start of study drug
(C1D1)

- Allogeneic stem cell transplant (AlloSCT) within 60 days prior to start of study drug
(C1D1)

- Active graft-versus-host disease

- Post-transplant lymphoproliferative disorders

- Active autoimmune disease, including motor neuropathy considered of autoimmune origin
and other central nervous system (CNS) autoimmune disease

- Known seropositive and requiring anti-viral therapy for human immunodeficiency (HIV)
virus, hepatitis B virus (HBV), or hepatitis C virus (HCV).

- History of Stevens-Johnson syndrome or toxic epidermal necrolysis

- Lymphoma with active CNS involvement at the time of screening, including
leptomeningeal disease

- Clinically significant third space fluid accumulation (i.e., ascites requiring
drainage or pleural effusion that is either requiring drainage or associated with
shortness of breath)

- Breastfeeding or pregnant

- Significant medical comorbidities

- Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14
days prior to start of study drug (C1D1), except shorter if approved by the Sponsor

- Use of any other experimental medication within 14 days prior to start of study drug
(C1D1)

- Planned live vaccine administration after starting study drug (C1D1)

- Failure to recover to Grade ≤1 (Common Terminology Criteria for Adverse Events version
4.0 [CTCAE v4.0]) from acute non-hematologic toxicity (Grade ≤2 neuropathy or
alopecia) due to previous therapy prior to screening

- Congenital long QT syndrome or a corrected QTcF interval of >480 ms at screening
(unless secondary to pacemaker or bundle branch block)

- Any other significant medical illness, abnormality, or condition that would, in the
Investigator's judgment, make the patient inappropriate for study participation or put
the patient at risk
We found this trial at
20
sites
Charleston, South Carolina 29425
Principal Investigator: Brian Hess, MD
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Melhem Solh, MD
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bologna, BO 40138
Principal Investigator: Pier L Zinzani, MD
?
mi
from
Bologna,
Click here to add this to my saved trials
Cleveland, Ohio 44012
Principal Investigator: Paolo F Caimi, MD
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Des Moines, Iowa 50309
Principal Investigator: Joshua Lukenbill, DO
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
Principal Investigator: Jasmine M Zain, MD
?
mi
from
Duarte, CA
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: Zulfiqar Zulfiqar, MD
?
mi
from
East Setauket, NY
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Principal Investigator: Alexander I. Spira, MD
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Fountain Valley, California 92708
Principal Investigator: Haresh S Jhangiani, MD
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Elizabeth Cull, MD
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Marietta, Georgia 30060
Principal Investigator: Steven L McCune, MD
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Juan P Alderuccio, MD
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33176
Principal Investigator: Guenther Koehne, MD
?
mi
from
Miami, FL
Click here to add this to my saved trials
Milwaukee, Wisconsin
Principal Investigator: Mehdi Hamadani, MD
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Olympia, Washington 98502
Principal Investigator: Joseph Ye, MD
?
mi
from
Olympia, WA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
Principal Investigator: Pierluigi Porcu, MD
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Brad Kahl, MD
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
505 Parnassus Ave
San Francisco, California 94143
(415) 476-1000
Principal Investigator: Weiyun Z Ai, MD, PhD
University of California, San Francisco Medical Center UCSF Medical Center is recognized throughout the world...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Temple, Texas 76508
Principal Investigator: Vinit G Karur, MD
?
mi
from
Temple, TX
Click here to add this to my saved trials
Whittier, California 90606
Principal Investigator: Michael Chung, MD
?
mi
from
Whittier, CA
Click here to add this to my saved trials